Author's response to reviews

Title: FOXP1 inhibits cell growth and reduces tumorigenicity of neuroblastoma

Authors:

Sandra Ackermann (sandra.ackermann@uk-koeln.de)
Hayriye Kocak (hayriye.kocak@web.de)
Barbara Hero (barbara.hero@uk-koeln.de)
Volker Ehemann (Volker.Ehemann@med.uni-heidelberg.de)
Yvonne Kahlert (yvonne.kahlert@uk-koeln.de)
André Oberthür (andre.oberthuer@uk-koeln.de)
Frederik Roels (frederik.roels@uk-koeln.de)
Jessica Theissen (jessica.theissen@uk-koeln.de)
Margarete Odenthal (m.odenthal@uni-koeln.de)
Frank Berthold (frank.berthold@uk-koeln.de)
Matthias Fischer (matthias.fischer@uk-koeln.de)

Version: 6
Date: 27 October 2014

Author's response to reviews: see over
Dear Dr. Rao,

thank you for giving us the opportunity to re-submit our manuscript “FOXP1 inhibits cell growth and reduces tumorigenicity of neuroblastoma” (MS: 5908954131316238) to BMC Cancer. We appreciate the editor’s comment and have addressed the issue raised as indicated below and in the revised version of our manuscript.

We provided more information on informed consent as follows:

“All patients were registered in respective clinical trials with written informed consent from the patient and/or a parent/legal guardian.”

Thank you very much for your kind consideration of our work. I hope that the revised manuscript is now acceptable for publication in BMC Cancer.

We look forward to hearing from you.

Sincerely,

Sandra Ackermann

Department of Pediatric Oncology

E-mail: sandra.ackermann@uk-koeln.de